Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10656025 | 0.98 | LMNA (0.66) | CYP3A4TSHRHSD17B10LMNABLM | |
| Azepexole SCHEMBL10434847 | 0.78 | LMNA (1.00) | CYP3A4TSHRHSD17B10LMNABLM | |
| Hydrochloric Acid SCHEMBL11074146 | 0.71 | MAPT (0.54) | CYP3A4TSHRHSD17B10LMNABLM | |
| SCHEMBL9775977 | 0.69 | MAPT (0.53) | CYP3A4LMNAMAPTADRA2AADRA2B | |
| Talipexole SCHEMBL49817 | 0.69 | DRD2 (1.00) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Talipexole SCHEMBL5605621 | 0.69 | DRD2 (1.00) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Talipexole SCHEMBL423325 | 0.68 | MAPT (1.00) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Talipexole SCHEMBL385161 | 0.68 | MAPT (1.00) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Talipexole SCHEMBL18203528 | 0.68 | MAPT (1.00) | LMNAMAPTADRA2AADRA2BADRA2C | |
| Talipexole SCHEMBL678761 | 0.67 | DRD2 (0.94) | LMNAMAPTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0005732-B1 | Use of 2-amino-oxazolo- or 2-amino-thiazolo-[5,4-d]azepines and acid-addition salts thereof for the manufacture of a medicament for the treatment of Angina Pectoris | Dr. Karl Thomae GmbH (DE) | 1988-06-15 | — | — | EP | claimed |
| US-4400378-A | THIAZOLO OR OXAZOLO COMPOUNDS | KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-08-23 | — | — | US | claimed |
| US-4259342-A | HYPOTENSIVE, SEDATIVE, ANTITUSSIVE, ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | claimed |
| EP-0005732-A1 | Use of 2-amino-oxazolo- or 2-amino-thiazolo-[5,4-d]azepines and acid-addition salts thereof for the manufacture of a medicament for the treatment of Angina Pectoris | Dr. Karl Thomae GmbH (DE) | 1979-12-12 | — | — | EP | claimed |
| US-20180177874-A1 | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | VEROSCIENCE, LLC | 2018-06-28 | — | — | US | disclosed |
| US-20180177874-A1 | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | VEROSCIENCE, LLC | 2018-06-28 | — | — | US | disclosed |
| US-20080200453-A1 | Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome | VEROSCIENCE, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200453-A1 | Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome | VEROSCIENCE, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-0005732-B1 | Use of 2-amino-oxazolo- or 2-amino-thiazolo-[5,4-d]azepines and acid-addition salts thereof for the manufacture of a medicament for the treatment of Angina Pectoris | Dr. Karl Thomae GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
| US-4400378-A | THIAZOLO OR OXAZOLO COMPOUNDS | KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-08-23 | — | — | US | disclosed |
| US-4259342-A | HYPOTENSIVE, SEDATIVE, ANTITUSSIVE, ANTIINFLAMMATORY | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177874-A1 | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | GPR119, GLP1R, PRLHR | CYP3A4 1203/4885TSHR 95/4885HSD17B10 539/4885 |
| US-20080200453-A1 | Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome | LIPG, LIPE, GPR119 | CYP3A4 787/4885TSHR 150/4885HSD17B10 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.